Vor Biopharma Inc.
VOR
$16.47
-$0.78-4.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.33% | 501.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.42% | -88.04% | |||
| Operating Income | -23.42% | 88.04% | |||
| Income Before Tax | 312.00% | 48.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 312.00% | 48.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 312.00% | 48.36% | |||
| EBIT | -23.42% | 88.04% | |||
| EBITDA | -23.35% | 87.94% | |||
| EPS Basic | 169.79% | 51.59% | |||
| Normalized Basic EPS | 169.54% | 50.56% | |||
| EPS Diluted | 169.79% | 51.59% | |||
| Normalized Diluted EPS | 169.54% | 50.56% | |||
| Average Basic Shares Outstanding | 203.75% | 6.68% | |||
| Average Diluted Shares Outstanding | 203.75% | 6.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||